Patients referred to Rush for stroke care benefit from a high-volume center’s level of experience combined with the personalized care at our specialized stroke clinics, including clinics for stroke prevention, stroke neurosurgery and stroke cardiology. These clinics bring together experts from many fields who evaluate patients and provide them with a consolidated, unified approach to their treatment plans, helping them weigh the risks and benefits of all their options.
Through our TeleStroke program, our clinicians work with community hospitals to deliver high-level stroke care across 10 affiliated emergency departments. This partnership and our collaborative approach enable us to manage even the most complex cases and have earned us recognition from the Joint Commission as a Comprehensive Stroke Center.
For at-risk patients, we offer strategies and resources that reduce their likelihood of stroke through management of related conditions and lifestyle changes. We provide patients with the opportunity to meet with stroke neurologists and neurosurgeons who use a wide range of medical and surgical techniques to prevent and treat cerebrovascular diseases that increase the risk of stroke. We also offer a variety of rehabilitation options, including physical, occupational and speech-language therapy. Our providers can refer patients to specialists who address the potential aftereffects of stroke, as well, such as depression, bowel and bladder issues and spasticity ranging from mild muscle stiffness to spasms, among other issues.
Patients have access to new treatments and technology that can improve outcomes. For example, patients who have difficulty with motor function impairment may benefit from the use of Vivistim, a magnetic implant device that can amplify the effects of physical and occupational therapy and improve neuroplasticity in the arms and hands. Our specialists also participate in clinical trials that may provide patients with treatment options not available anywhere else. We are currently the only site in the Midwest participating in the cAPPriccorn-1 phase 2 study. This is a trial of a drug designed to slow progression of cerebral amyloid angiopathy, a cause of hemorrhagic stroke that often occurs in patients with Alzheimer’s disease.